Market Spotlight: Hidradenitis Suppurativa
|出版日||ページ情報||英文 38 Pages
|注目市場の分析：汗腺膿瘍 Market Spotlight: Hidradenitis Suppurativa|
|出版日: 2020年02月14日||ページ情報: 英文 38 Pages||
This Market Spotlight report covers the Hidradenitis Suppurativa market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
All of the approved drugs for hidradenitis suppurativa (HS) target tumor necrosis factor-alpha. These therapies are administered via the subcutaneous route, while Humira is also available in an intravenous formulation.
The majority of industry-sponsored drugs in active clinical development for HS are in Phase II. Therapies in development for HS target tumor necrosis factor-alpha, interleukin-17, interleukin-1, interleukin-23, JAK/STAT, cluster of differentiation 40, and the C5a receptor. These therapies are administered via the oral, intravenous, and subcutaneous routes.
High-impact upcoming events for drugs in the HS space comprise topline Phase II trial results for Avacopan and Iscalimab. The overall likelihood of approval of a Phase I dermatology-general asset is 25.2%, and the average probability a drug advances from Phase III is 75%. Drugs, on average, take 8.1 years from Phase I to approval in the dermatology-general space, as well as in the overall dermatology space.
There have been only eight licensing and asset acquisition deals involving HS drugs during 2015-20. The $750m definitive agreement signed in December 2019 between Janssen Pharmaceutical and Xbiotech, under which Janssen Pharmaceutical has acquired all rights to Xbiotech's bermekimab, an anti-IL-1alpha monoclonal antibody (mAb) in Phase II development for the treatment of atopic dermatitis and HS, was the largest deal.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for HS have been in the early and midphases of development, with 83% of trials in Phase I-II, and only 17% in Phase III-IV.
The US has the lead in terms of the number of HS clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
AbbVie and Abbott have the highest number of completed clinical trials for HS, with two trials each.
AbbVie is the only sponsor to have initiated a Phase III and Phase IV trial in HS.